Back to List View Graph View

Celecoxib

Celecoxib is a selective cyclooxygenase-2 (COX-2) inhibitor belonging to the nonsteroidal anti-inflammatory drug (NSAID) class, distinguished by its preferential blockade of the inducible COX-2 isoform over the constitutively expressed COX-1.

Where the papers sit

12 papers from the last 6 months study celecoxib directly · updated from PubMed 12 Nov 2026

Those 12 do not share a common subject.

  • Celecoxib appears across pain control, osteoarthritis, desmoid-type fibromatosis, cancer nanomedicine, drug interactions, and solid-state formulation studies. Some papers assess clinical efficacy or safety, while others develop delivery systems or analytical methods. The endpoints range from bleeding and pain to pharmacokinetics, cytotoxicity, and molecular material behavior. These topics share drug involvement but no single biological question or research direction.

    12 papers

NEW DIRECTION

Celecoxib functions as a solid-state crystallization modifier in an active-pharmaceutical-ingredient mixture

The co-amorphous/crystalline celecoxib–etoricoxib system treated celecoxib not as a pharmacological agent but as a component whose intermolecular interactions determine material stability. Instead of following conventional composition-based glass-transition mixing rules, the mixture showed a non-monotonic glass-transition maximum near the equimolar ratio, while etoricoxib strongly suppressed celecoxib recrystallization through hydrogen-bonded heterosynthons. This gives celecoxib a formulation-material role in controlling amorphous-solid stability 42969731Nov.

NEW DIRECTION

Celecoxib acts as a clinically relevant modifier of tramadol bioactivation

The randomized crossover study of orally administered tramadol in healthy volunteers examined celecoxib as a drug-interaction agent rather than only as a co-administered analgesic. Celecoxib pretreatment did not change tramadol exposure but reduced formation of its CYP2D6-dependent active metabolite, O-desmethyltramadol, showing that celecoxib can alter opioid bioactivation and potentially its pharmacological effects. This makes celecoxib’s interaction with tramadol disposition a treatment-relevant role distinct from its direct anti-inflammatory action 42272128Jun.

celecoxib chemical structure

Papers

The 12 papers from the last 6 months that study celecoxib directly, newest first, by theme and by study type. Study types come from PubMed publication types and MeSH headings.

By theme

No clear themes (12)
  1. Non-Monotonic Glass Transition Behavior as a Molecular Signature of Strong Interactions in Co-Amorphous and Crystalline Celecoxib-Etoricoxib Systems. Molecular pharmaceutics · 2 Nov 2026 PMID 42969731
  2. Celecoxib as a non-inferior alternative to ibuprofen in post-tonsillectomy pain and bleeding control. International journal of pediatric otorhinolaryngology · 13 Oct 2026 PMID 42868944
  3. Randomised comparative effectiveness trial evaluating the efficacy and safety of acupuncture-related integrative therapy combined with celecoxib for chronic pain in patients with knee osteoarthritis: protocol. BMJ open · 24 Sept 2026 PMID 42785936
  4. Efficacy of celecoxib and methotrexate-vinblastine regimen in desmoid-type fibromatosis: A retrospective cohort study. Medicine · 19 Sept 2026 PMID 42760667
  5. Efficacy and Safety of Celecoxib Combined With Jintiange Capsules for the Treatment of Knee Osteoarthritis: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial. Medical science monitor : international medical journal of experimental and clinical research · 14 Sept 2026 PMID 42733221
  6. Green analytical methods for quantification of a new combination therapy for amyotrophic lateral sclerosis: assessment by EPPI framework. Scientific reports · 21 Aug 2026 PMID 42624937
  7. CD44-Targeted Delivery of Melittin and Celecoxib via Hyaluronic Acid-Coated Polymersomes for Synergistic Anti-Inflammatory Therapy. ChemMedChem · 23 Jul 2026 PMID 42493250
  8. Dual-drug-loaded lipid-based formulation for colon cancer therapeutics: in vitro optimization and characterization. Drug development and industrial pharmacy · 17 Jul 2026 PMID 42467220
  9. Hijacking radiotherapy-induced chemokines with self-assembled molecular decoys for glioblastoma radio-immunotherapy. Journal of controlled release : official journal of the Controlled Release Society · 2 Jul 2026 PMID 42392408
  10. Effects of Celecoxib and Etoricoxib on the Pharmacokinetics and Pharmacological Effects of Orally Administered Tramadol: A Randomised Controlled Trial. Basic & clinical pharmacology & toxicology · 11 Jun 2026 PMID 42272128
  11. Spatiotemporally programmed nanomedicine engineering to resolve conflicting immunosignals in triple-negative breast cancer. Signal transduction and targeted therapy · 3 Jun 2026 PMID 42236688
  12. Anticancer activity of fluoxetine Janus dendrimer against cancer cells. Artificial cells, nanomedicine, and biotechnology · 21 May 2026 PMID 42167254

By study type

Clinical trials (3)
  1. Randomised comparative effectiveness trial evaluating the efficacy and safety of acupuncture-related integrative therapy combined with celecoxib for chronic pain in patients with knee osteoarthritis: protocol. BMJ open · 24 Sept 2026 PMID 42785936
  2. Efficacy and Safety of Celecoxib Combined With Jintiange Capsules for the Treatment of Knee Osteoarthritis: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial. Medical science monitor : international medical journal of experimental and clinical research · 14 Sept 2026 PMID 42733221
  3. Effects of Celecoxib and Etoricoxib on the Pharmacokinetics and Pharmacological Effects of Orally Administered Tramadol: A Randomised Controlled Trial. Basic & clinical pharmacology & toxicology · 11 Jun 2026 PMID 42272128
Observational studies and case reports (2)
  1. Celecoxib as a non-inferior alternative to ibuprofen in post-tonsillectomy pain and bleeding control. International journal of pediatric otorhinolaryngology · 13 Oct 2026 PMID 42868944
  2. Efficacy of celecoxib and methotrexate-vinblastine regimen in desmoid-type fibromatosis: A retrospective cohort study. Medicine · 19 Sept 2026 PMID 42760667
Human data, design not indexed (2)
  1. Green analytical methods for quantification of a new combination therapy for amyotrophic lateral sclerosis: assessment by EPPI framework. Scientific reports · 21 Aug 2026 PMID 42624937
  2. Dual-drug-loaded lipid-based formulation for colon cancer therapeutics: in vitro optimization and characterization. Drug development and industrial pharmacy · 17 Jul 2026 PMID 42467220
Preclinical: animal, cell and lab studies (5)
  1. Non-Monotonic Glass Transition Behavior as a Molecular Signature of Strong Interactions in Co-Amorphous and Crystalline Celecoxib-Etoricoxib Systems. Molecular pharmaceutics · 2 Nov 2026 PMID 42969731
  2. CD44-Targeted Delivery of Melittin and Celecoxib via Hyaluronic Acid-Coated Polymersomes for Synergistic Anti-Inflammatory Therapy. ChemMedChem · 23 Jul 2026 PMID 42493250
  3. Hijacking radiotherapy-induced chemokines with self-assembled molecular decoys for glioblastoma radio-immunotherapy. Journal of controlled release : official journal of the Controlled Release Society · 2 Jul 2026 PMID 42392408
  4. Spatiotemporally programmed nanomedicine engineering to resolve conflicting immunosignals in triple-negative breast cancer. Signal transduction and targeted therapy · 3 Jun 2026 PMID 42236688
  5. Anticancer activity of fluoxetine Janus dendrimer against cancer cells. Artificial cells, nanomedicine, and biotechnology · 21 May 2026 PMID 42167254